Search Results

Phoenix PharmaLabs, Inc. today announced that in vivo studies demonstrated that the company’s lead compound, PPL-138, reduced symptoms of PTSD and decreased alcohol consumption in a rat model of PTSD/AUD (alcohol abuse disorder).

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company.

According to a study published in Nature Communications, research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix, shows how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions, called enhancers, can lead to Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV), a rare, lethal, genetic lung disease which causes respiratory failure in newborns and infants.

Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.

Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix shows normalizing cancer tumor vessels and alleviating low oxygen levels in the tumor microenvironment can improve the effectiveness of chemotherapy treatment in lung cancer, according to a paper published in EMBO Molecular Medicine.

Phoenix PharmaLabs, Inc. (https://phoenixpharmalabs.com), a private company developing potent, non-addictive treatments for pain and addiction, today announced the receipt of an $8.7 million grant from the National Institute on Drug Abuse (NIDA).

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA™ in Canada) in people living with amyotrophic lateral sclerosis (ALS).

Aclarion, Inc. announced that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.